News
RIGL
1.080
+2.86%
0.030
Weekly Report: what happened at RIGL last week (0408-0412)?
Weekly Report · 4d ago
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
NASDAQ · 04/12 12:21
RIGEL PHARMACEUTICALS: ON APRIL 11, ENTERED AMENDMENT TO CREDIT & SECURITY DEAL OF SEPT 27, 2019 TO EXTEND MATURITY FOR TERM LOANS TO SEPT 1, 2027
Reuters · 04/12 12:09
RIGEL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/10 20:30
Weekly Report: what happened at RIGL last week (0401-0405)?
Weekly Report · 04/08 09:04
Market Sentiment Around Loss-Making Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. Announced a latest loss of US$25m for its most recent financial year. The company is expected to grow at an average annual rate of 55%. The company has negative equity on its balance sheet and is on the verge of becoming profitable. Rigel pharmaceuticals engages in discovering and developing therapies for hematologic disorders and cancer.
Simply Wall St · 04/04 13:33
Rigel Publishes Data On REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML In Leukemia & Lymphoma
Benzinga · 04/04 12:11
RIGEL PHARMACEUTICALS INC <RIGL.O>: JEFFERIES RAISES TARGET PRICE TO $1.65 FROM $1
Reuters · 04/02 04:40
Monday Sector Laggards: Biotechnology, Water Utilities
NASDAQ · 04/01 16:08
Weekly Report: what happened at RIGL last week (0325-0329)?
Weekly Report · 04/01 09:04
Weekly Report: what happened at RIGL last week (0318-0322)?
Weekly Report · 03/25 09:04
Weekly Report: what happened at RIGL last week (0311-0315)?
Weekly Report · 03/18 09:04
Press Release: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. As Chief Medical Officer. Dr. RojKjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience. She is a board-certified hematologist with a focus on hematology and cancer.
Dow Jones · 03/12 12:05
Weekly Report: what happened at RIGL last week (0304-0308)?
Weekly Report · 03/11 09:04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) came out with its full-year results last week. Revenues of US$116m were in line with expectations. The company is expected to grow faster than the wider industry. The consensus forecast for Rigel Pharmaceuticals is for revenues to rise to US$148.4m in 2024. The analysts are also lowering their loss per share forecasts for next year. The firm's consensus price target rose 8.1% following the results.
Simply Wall St · 03/08 11:34
Rigel Pharmaceuticals Price Target Raised to $4.00/Share From $3.00 by Citigroup
Dow Jones · 03/07 14:41
Rigel Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 03/07 14:41
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4
Benzinga · 03/07 14:30
New Corporate Activity and Growth Risk for Rigel Pharmaceuticals – What’s the Latest?
TipRanks · 03/07 06:02
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 03/06 17:44
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.